source
- AstraZeneca’s GLP-1 obesity pill shows 10.5% average weight loss after six months in Phase 2 trialAstraZeneca reported data from its Phase 2 study of a GLP-1 based oral obesity treatment. The trial showed participants lost an average of 10.5% of body weight after six months of therapy. The re…
- Arvinas’ ‘Protac’ breast cancer drug cleared by FDAKnown as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.BioPharma Dive · 4mo ago↗ source